GlassScriptPhysician profile
Martha Garzon
NPI 1881673960
$2,061.48
in general payments reported to CMS, 2019-2025
27 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $70.81 · 2021: $230 · 2022: $406 · 2023: $495 · 2024: $276 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.76 |
| Education | $195.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $360.45 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $218.31 | 2021-2024 | |
| Coopersurgical, INC. | $195.43 | 2020-2025 | Paragard T 380a |
| Hologic Sales and Service, LLC | $163.69 | 2022-2025 | Aptima, Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Avion Pharmaceuticals | $120.43 | 2019-2021 | |
| Innovation Technologies INC | $120.00 | 2021 | |
| Abbvie INC. | $117.35 | 2019-2023 | |
| Pfizer INC. | $113.16 | 2019-2025 | |
| Millicent US INC | $95.28 | 2024-2025 | Femring, Intrarosa |
| Therapeuticsmd, INC. | $66.78 | 2019 | |
| Myovant Sciences INC. | $56.57 | 2021-2022 | |
| Smith+Nephew, INC. | $46.96 | 2022-2024 | Pico 14 |
| Scynexis, INC. | $45.68 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.89 | 2020-2025 | |
| Exact Sciences Corporation | $43.29 | 2023 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $36.17 | 2019 | |
| Lupin INC. | $33.56 | 2019 | |
| Amag Pharmaceuticals, INC. | $28.86 | 2019 | |
| Shield Therapeutics INC | $22.11 | 2024 | |
| Mylan Pharmaceuticals INC. | $21.87 | 2022 | |
| Novo Nordisk INC | $21.75 | 2023 | Wegovy |
| Sumitomo Pharma America, INC. | $17.86 | 2023 | Myfembree |
| Organon LLC | $17.50 | 2024 | |
| Evofem Biosciences, INC. | $17.50 | 2025 | Phexxi, Solosec, Phexx |
| Amgen INC. | $13.00 | 2019 | |
| Allergan, INC. | $12.75 | 2019 | |
| Covidien LP | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Garzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.